Mariner
TSHA icon

Mariner’s Taysha Gene Therapies TSHA Stock Holding History

Mariner’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$794K Buy
+116,582
New +$690K ﹤0.01% 2129
2025
Q2 		– Sell
-58,490
Closed -$81.3K – 3696
2025
Q1 		$81.3K Buy
58,490
+148
+0.3% +$248 ﹤0.01% 3225
2024
Q4 		$101K Buy
58,342
+45,006
+337% +$93.4K ﹤0.01% 3187
2024
Q3 		$26.8K Buy
+13,336
New +$29.3K ﹤0.01% 3230

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mariner's TSHA Position: Q2 2026 in Review

Mariner opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 116,582 shares worth $794K. The stake represents ﹤0.01% of the portfolio and ranks #2129 among its holdings. This is a return to the name: Mariner previously reported a position in TSHA as recently as Q1 2025.

Mariner first reported a position in TSHA in Q3 2024 and has held it in 4 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Mariner held 116,582 shares of Taysha Gene Therapies worth $794K as of Q2 2026.
  • Taysha Gene Therapies was a new Mariner position in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2129 holding.
  • Mariner first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 4 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.